Lauren Martens is the vice president of biology at Neumora Therapeutics, where she focuses on advancing neurodegeneration programs toward the clinic in support of the development of disease-modifying therapeutics for brain disorders with high unmet need. Her research career has focused on the development of a variety of disease-relevant model systems used to validate new targets, elucidate mechanism-of-action of potential therapeutics, understand cell type specificity and selectivity and support early biomarker development. These platforms have enabled advancement of preclinical programs in close collaboration with her colleagues in data science, medicinal chemistry and translation. She has focused on precision neuroscience approaches throughout her biotech career at Neumora, Tiaki Therapeutics, Dementia Discovery Fund and Forum/En Vivo to decrease patient heterogeneity for treating people with Parkinson’s disease, Alzheimer’s disease, ALS or frontotemporal dementia. She received her PhD at the University of California, San Francisco, where she worked at the Gladstone Institutes.